---
title: NeoGenomics (NEO)
layout: default
nav_order: 1998
---

# NeoGenomics
{: .fs-9 }

{: .label .label-purple }

Moat: 2/5

{: .label .label-blue }

Understandability: 3/5

{: .label .label-green }

Balance Sheet Health: 3/5

NeoGenomics, Inc. is a U.S.-based clinical laboratory company that offers a broad range of diagnostic, prognostic, and predictive tests for oncology and other complex conditions.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=NEO+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/NEO/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning }
>The moat, understandability, and balance sheet health scores reflect a conservative evaluation to ensure a margin of safety in any assessment.



{: .highlight }
NeoGenomics, while demonstrating some elements of a moat, does not present a strong and sustainable moat and scores 2 / 5.

The company's moat is largely derived from the *technical expertise* and its *reputation* for accurate diagnoses, which are essential in a complex market like oncology diagnostics. However, these elements are not impossible for competitors to replicate or overcome.

The main factors that influence the moat rating and its justification are described below. 

*   **Limited Barriers to Entry:** While the clinical laboratory testing industry requires certifications and accreditations, these are not prohibitive for well-capitalized new entrants.
*   **Competition:** Many players, including other large labs (such as Quest Diagnostics, LabCorp), as well as smaller, more focused companies, compete directly with NeoGenomics. There is a lack of consolidation. There is the threat of substitute diagnostic technology.
*  **Limited Pricing Power**: Due to the fragmented nature of the market and the nature of services that are commodifiable to a certain degree, NeoGenomics has limited pricing power and depends on winning contracts rather than command premium pricing.
*   **Intangible Assets**: While the company has established a known brand in the industry, it is not particularly strong. The company is constantly working on research and innovation; its results will determine if these can give rise to a durable advantage. 
*   **Switching Costs**: There are some switching costs given the need to establish quality assurance and regulatory frameworks, it doesn't present very high switching costs.

Legitimate risks that could harm the moat and the business resilience are numerous, and are mentioned below.

*   **Regulatory changes:** The company's operations are heavily dependent on regulations, and any adverse changes in those regulations could severely affect its financial performance and moat. 
*  **Pricing pressures**: Consolidation among healthcare providers and payers could put substantial pressure on prices. Since contracts are generally renegotiated frequently, any decrease in prices could lead to a considerable drop in profitability.
*   **Technology Risk:** New diagnostic technologies, particularly those involving genomics, could make the company's current testing practices obsolete. This can cause a fast erosion of the moat.
*   **Loss of Key Contracts:** Reliance on contracts with large payers means that loss of these contracts could lead to a significant revenue loss.
*   **Increased Competition:** Increased competition can put downward pressure on prices and impact the ability of NEO to win new clients and contracts.
*    **Execution Risks:** Integration of acquisitions and implementation of its business model, are both difficult and costly. 
*   **Litigation and Liability Risks**: Any malpractice lawsuits, or other legal proceedings could severely affect NEO's financial and reputational health.

{: .new }
**Recent Concerns and Problems:**

*   The most recent earnings calls and reports have shown mixed performance, with revenues lower than analysts expected, and an increase in net loss of operations.
*   The stock price of the company has been severely affected by these results. 
*   Management's recent emphasis on reducing costs and restructuring.
*  In 2023, they saw a decrease in revenue per clinical test due to "less complex" tests.
*  Declining operating margins due to increased staffing costs. 
*  Decrease in the share price due to overall disappointing results and management's decision to not provide an earnings outlook for 2024.

The company's business primarily consists of *clinical services* and *advanced diagnostics*, and has had a history of revenue growth driven by acquisitions, expansions in capacity, and new testing offerings. The distribution of revenues and further details are as follows.

*   **Clinical Services:** This segment provides tests to hospitals, physicians, and other clinical laboratories to assist in diagnosis, prognosis, and detection of diseases such as cancer. It covers cytogenetics, fluorescence in situ hybridization (FISH), histology, immunohistochemistry, and flow cytometry. Revenues in 2022 and 2021 were $328 and $306 million, respectively. 
*  **Advanced Diagnostics:** Provides tests that combine data from clinical and genomics tests to identify patterns for more individualized treatment. The new technology is mostly based around next-generation sequencing (NGS) and companion diagnostics to identify those who would benefit from specific therapies. This segment accounted for about $159 and $124 million in 2022 and 2021, respectively.
*  **Pharma Services** Helps pharmaceutical and biotechnology companies in developing new therapies.
* The overall company revenue in 2022 was \$484 million which was 10.9% greater than the revenue in 2021.

 The company is operating in a market that is expected to grow rapidly due to growing rates of cancer incidence and development of novel diagnostics. The business is highly influenced by both the healthcare industry and technological advancement. The competitive landscape is fragmented, and the need to continuously innovate and offer better quality tests is crucial for a company to succeed.

The company claims that they provide a more comprehensive diagnostic solution by offering a wide array of tests and integrating advanced technologies, coupled with a consultative approach and focus on cancer. This is used as a differentiator against competitors. They also highlight that they have focused R\&D to develop their own proprietary methods that will provide them with sustainable advantages. However, there is intense competition in many fields from bigger labs.

Let us talk about the financials in details.

*  **Revenue**: Despite the challenging economic environment the company has showed a constant growth in revenues. 2022 saw revenue of 484 million, a 10.9% increase YoY. For the first 9 months of 2023 revenues were $368.8 million, a 3.2% increase YoY. However, the consensus view for 2023 revenues is lower than their projections. 
*  **Profitability**: In 2022 and 2021 the operating margin was 0.3% and -15.7%. In the last earning reports it is -26.8% , they have been unprofitable for years. The main reason for low margins is the rise in input costs and high personnel costs. Gross margin in 2022 was 40.4% compared to 45.1% for 2021. Operating costs have increased by 13%, compared to the YoY period. Cost of revenue has increased by 15.4% YoY. Adjusted EBITDA in 2022 was -$53 million, while in 2021 it was $7.1 million.
*  **Balance Sheet**: As of September 30, 2023, NEO had $301.5 million of cash. Long term debt was $422 million, and the total liabilities were $694.9 million. The company has been burning a lot of cash due to poor margins.
*  **Cash flow**: In the nine months ended September 30, 2023, the company used cash for operation to the tune of $101.2 million. They have an additional free cash flow burn of over 28 million.

{: .highlight }
The company is currently unprofitable, has been for quite some time now, and has a strained balance sheet with high debt. These points toward a troubled outlook for NEO.

  The understandability of the business is rated at 3/5. The business is very complicated. It requires an understanding of biochemistry and biology, medicine, and healthcare systems, as well as the details of various regulations that impact the healthcare industry.

The balance sheet of NEO is rated 3/5. It is not very healthy due to considerable long term debt and lack of profitability, which means continuous cash burn. This makes it only average in terms of financial health. There is significant amount of goodwill and intangible assets that further weakens the balance sheet, however, they have a reasonable cash balance.

In conclusion, while NeoGenomics has a brand and technical expertise, the business faces multiple issues including weak profitability, high competition, and other headwinds to future growth. The risks are prominent and the company needs to find a way to create a sustainable competitive advantage or moat to be considered a long term stable business.